MRI Guided Radiation Therapy for the Treatment of High Risk Prostate Cancer
Status:
Recruiting
Trial end date:
2026-06-01
Target enrollment:
Participant gender:
Summary
This phase II trial tests whether magnetic resonance imaging (MRI)-guided hypofractionated
radiation therapy works to reduce treatment time and side effects in patients with high risk
prostate cancer. MRI-guided hypofractionated radiation therapy delivers higher doses of
radiation therapy over a shorter period of time directly to diseased tissue, reducing damage
to healthy tissue. Using MRI-guided radiation therapy on areas of the prostate and pelvic
lymph nodes may shorten overall treatment time compared to the longer standard of care
therapy and may reduce the number and/or duration of side effects.